TY - JOUR
AU - Yamanaka, Hisashi
AB - Abstract We aimed to demonstrate the incidence of serious respiratory infections in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ) monotherapy. We analyzed the incidence of serious respiratory infections in 601 RA patients enrolled in TCZ clinical trials and their extension studies (TCZ cohort) and in 601 age- and sex-standardized RA patients treated in daily clinical practice at Tokyo Women’s Medical University (IORRA subsample cohort). The rates of serious respiratory infections were 1.77 per 100 patient-years from 1999 to 2008 in the TCZ cohort and 0.53 per 100 patient-years from 2000 to 2009 in the IORRA subsample cohort. With the IORRA subsample cohort regarded as a standard population, the standardized incidence ratio (SIR) of serious respiratory infection in the TCZ cohort was 3.64 [95% confidence interval (CI) 2.56–5.01], standardized for age and sex; 2.35 (95% CI 1.66–3.24), standardized for age sex, and corticosteroid use; 1.85 (95% CI 1.30–2.55), standardized for age sex, and pre-existing pulmonary involvement; and 2.41 (95% CI 1.68–3.34) standardized for age sex, and disease activity. The risk of serious respiratory infection in the TCZ cohort was approximately double that in the IORRA subsample cohort after standardizing for corticosteroid use, pre-existing pulmonary involvement, or disease activity. This is comparable to the risk reported when tumor necrosis factor (TNF) inhibitors are used. Rheumatoid arthritis, Tocilizumab, Pneumonia, Infection References Doran MF , Crowson CS, Pond GR, O'Fallon WM, Gabriel SE . Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum . 2002 ; 46 : 2287 – 93 . Google Scholar OpenURL Placeholder Text WorldCat Smitten AL , Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis . J Rheumatol . 2008 ; 35 : 387 – 93 . Google Scholar PubMed OpenURL Placeholder Text WorldCat Shinomiya F , Mima N, Nanba K, Tani K, Nakano S, Egawa H, et al. Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period . Mod Rheu-matol . 2008 ; 18 : 165 – 9 . Google Scholar Crossref Search ADS WorldCat Bjomadal L , Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95 . J Rheumatol . 2002 ; 29 : 906 – 12 . Google Scholar PubMed OpenURL Placeholder Text WorldCat Nakajima A , Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheuma-toid arthritis based on a large observational cohort, IORRA . Scand J Rheumatol . 2010 ; 39 : 360 – 7 . Google Scholar Crossref Search ADS PubMed WorldCat Nam JL , Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheu-matic drugs: a systematic literature review informing the EULAR recommendations for the management of RA . Ann Rheum Dis . 2010 ; 69 : 976 – 86 . Google Scholar Crossref Search ADS PubMed WorldCat Keystone EC , Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial . Arthritis Rheum . 2004 ; 50 : 1400 – 11 . Google Scholar Crossref Search ADS PubMed WorldCat St Clair EW , van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial . Arthritis Rheum . 2004 ; 50 : 3432 – 43 . Google Scholar Crossref Search ADS PubMed WorldCat Listing J , Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al . Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum . 2005 ; 52 : 3403 – 12 . Google Scholar OpenURL Placeholder Text WorldCat Curtis JR , Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists . Arthritis Rheum . 2007 ; 56 : 1125 – 33 . Google Scholar Crossref Search ADS PubMed WorldCat Takeuchi T , Tatsuki Y, Nagami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis . Ann Rheum Dis . 2008 ; 67 : 189 – 94 . Google Scholar Crossref Search ADS PubMed WorldCat Koike T , Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan . J Rheumatol . 2009 ; 36 : 898 – 906 . Google Scholar Crossref Search ADS PubMed WorldCat Nishimoto N , Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis . Phase I/II clinical study. J Rheumatol . 2003 ; 30 : 1426 – 35 . Google Scholar OpenURL Placeholder Text WorldCat Nishimoto N , Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial . Arthritis Rheum . 2004 ; 50 : 1761 – 9 . Google Scholar Crossref Search ADS PubMed WorldCat Nishimoto N , Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy . Mod Rheumatol . 2009 ; 19 : 12 – 9 . Google Scholar Crossref Search ADS PubMed WorldCat Nishimoto N , Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab . Ann Rheum Dis . 2007 ; 66 : 1162 – 7 . Google Scholar Crossref Search ADS PubMed WorldCat Genovese MC , McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with toc-ilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modify-ing antirheumatic drug therapy study . Arthritis Rheum . 2008 ; 58 : 2968 – 80 . Google Scholar Crossref Search ADS PubMed WorldCat Emery P , Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-con-trolled trial . Ann Rheum Dis . 2008 ; 67 : 1516 – 23 . Google Scholar Crossref Search ADS PubMed WorldCat Smolen JS , Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008 ; 371: 987 – 97 . Nishimoto N , Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol . 2010 ; 20 : 222 – 32 . Nishimoto N , Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study . Ann Rheum Dis . 2009 ; 68 : 1580 – 4 . Google Scholar Crossref Search ADS PubMed WorldCat Arnett FC , Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis . Arthritis Rheum . 1988 ; 31 : 315 – 24 . Google Scholar Crossref Search ADS PubMed WorldCat Yamanaka H , Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA) . Mod Rheumatol . 2007 ; 17 : 98 – 105 . Google Scholar Crossref Search ADS PubMed WorldCat Yamada T , Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan . Ann Rheum Dis . 2006 ; 65 : 1661 – 3 . Google Scholar Crossref Search ADS PubMed WorldCat Tanaka E , Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability . Ann Rheum Dis . 2008 ; 67 : 1153 – 8 . Google Scholar Crossref Search ADS PubMed WorldCat Matsuda Y , Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3763 patients with rheumatoid arthritis . Arthritis Rheum . 2003 ; 49 : 784 – 8 . Google Scholar Crossref Search ADS PubMed WorldCat Wolfe F , Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associa-tions with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum . 2006 ; 54 : 628 – 34 . Dixon W , Silman A. Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al . Arthritis Res Ther . 2006 ; 8 : 111 . Google Scholar Crossref Search ADS PubMed WorldCat Dixon WG , Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies . Arthritis Rheum . 2007 ; 56 : 2896 – 904 . Google Scholar Crossref Search ADS PubMed WorldCat Greenberg JD , Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry . Ann Rheum Dis . 2010 ; 69 : 380 – 6 . Google Scholar Crossref Search ADS PubMed WorldCat Grijalva CG , Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR . Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) . 2010 ; 49 : 82 – 90 . Google Scholar OpenURL Placeholder Text WorldCat This content is only available as a PDF. © 2012 Japan College of Rheumatology This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) © 2012 Japan College of Rheumatology
TI - Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab
JO - Modern Rheumatology
DO - 10.3109/s10165-011-0488-6
DA - 2012-02-01
UR - https://www.deepdyve.com/lp/oxford-university-press/incidence-of-serious-respiratory-infections-in-patients-with-u2ikbZUBzk
SP - 122
EP - 127
VL - 22
IS - 1
DP - DeepDyve
ER -